idiopath
pulmonari
fibrosi
ipf
one
refractori
lung
diseas
lack
effect
therapi
progress
pulmonari
fibrosi
also
acut
exacerb
defin
clinic
signific
deterior
unidentifi
caus
attribut
poor
surviv
patient
patholog
find
lung
ipf
patient
afflict
acut
exacerb
diffus
alveolar
damag
consist
find
observ
acut
lung
injuri
variou
caus
characterist
underli
usual
interstiti
pneumonia
howev
etiolog
acut
exacerb
ipf
yet
elucid
high
mobil
group
protein
origin
identifi
nuclear
nonhiston
protein
dnabind
domain
implic
import
endogen
danger
signal
molecul
well
late
mediat
system
inflamm
septic
shock
thu
put
role
pathogenesi
acut
lung
injuri
addit
sever
studi
identifi
bbox
domain
import
mani
proinflammatori
properti
includ
cytokin
releas
releas
passiv
cellular
necrosi
almost
cell
nucleu
signal
neighbor
cell
case
ongo
damag
howev
also
secret
activ
immun
cell
monocyt
macrophag
dendrit
cell
receptor
advanc
glycat
end
product
rage
first
receptor
demonstr
bind
signal
rage
found
promot
chemotaxi
product
cytokin
process
involv
activ
transcript
factor
nuclear
nevertheless
contribut
pathogenesi
acut
exacerb
ipf
determin
yet
previous
report
heterogen
remodel
alveolar
capillari
lung
patient
ipf
alveolar
capillari
decreas
fibrot
lesion
increas
nonfibrot
alveolar
septa
around
fibrot
lesion
vegf
potent
angiogen
factor
augment
sinc
vegf
also
potent
induc
vascular
permeabl
capillari
dens
lesion
nonfibrot
alveolar
septa
consid
leaki
thu
suscept
alveolar
infiltr
trigger
inflammatori
mediat
acut
lung
injuri
also
interest
thrombomodulin
endotheli
anticoagul
cofactor
highli
express
alveolar
capillari
normal
control
lung
less
ipf
lung
ntermin
domain
thrombomodulin
bind
prevent
interact
rage
thu
suppress
induct
proinflammatori
event
context
examin
bronchoalveolar
lavag
fluid
serial
sampl
patient
ipf
acut
exacerb
along
lung
tissu
specimen
biopsi
patient
stabl
ipf
autopsi
ipf
patient
die
acut
exacerb
evalu
involv
inflammatori
mediat
pathogenesi
acut
exacerb
ipf
clinic
samplesacut
exacerb
idiopath
pulmonari
fibrosi
diagnos
accord
japanes
diagnost
criteria
establish
essenti
compat
criteria
idiopath
pulmonari
fibrosi
clinic
research
network
investig
bronchoalveolar
lavag
fluid
sampl
tosei
gener
hospit
seven
patient
ipf
two
four
instanc
acut
exacerb
patient
allow
diagnost
exclus
infect
sampl
store
degre
surgic
biopsi
ten
patient
stabl
ipf
autopsi
lung
eight
patient
ipf
die
acut
exacerb
obtain
tohoku
univers
hospit
diseasefre
lung
tissu
autopsi
three
patient
without
chronic
lung
diseas
also
examin
control
lung
tissu
fix
buffer
formalin
imbed
paraffin
wax
written
inform
consent
obtain
patient
use
clinic
sampl
approv
ethic
committe
tohoku
univers
measur
balf
measur
highli
sensit
specif
elisa
method
shinotest
kanagawa
japan
report
previous
brief
black
polystyren
microtit
plate
corn
laboratori
scienc
corn
ny
coat
polyclon
antibodi
phosphatebuff
salin
pb
wash
time
pb
contain
block
bovin
serum
albumin
hour
wash
dilut
standard
sampl
dilut
moll
tri
ph
moll
nacl
contain
bsa
ad
well
incub
hour
room
temperatur
wash
antihuman
peroxidaseconjug
monoclon
antibodi
ad
incub
room
temperatur
minut
anoth
wash
step
psatto
lumigen
southfield
mi
ad
luminesc
measur
micropl
luminesc
reader
diaiatron
tokyo
japan
concentr
cytokin
balf
sampl
consist
interleukin
il
granulocyt
coloni
stimul
factor
gcsf
monocyt
chemotact
granulocytemacrophagecoloni
stimul
factor
gmcsf
macrophag
inflammatori
protein
mip
interferon
ifn
tumor
necrosi
factor
determin
use
bioplex
biorad
laboratori
inc
follow
manufactur
protocol
total
balf
sampl
also
measur
use
enzym
immunoassay
eia
produc
mbc
laboratori
inc
tokyo
japan
viru
isolationeach
balf
sampl
subject
viru
isol
micropl
method
viru
research
center
nation
hospit
organ
sendai
japan
short
specimen
place
transport
medium
compos
eagl
minimum
essenti
medium
sigma
st
loui
mo
usa
gelatin
contain
unitsml
penicillin
g
mgml
streptomycin
centrifug
g
min
supernat
fraction
inocul
cultur
cell
human
embryon
fibroblast
use
cell
line
vero
hmvii
mdck
cell
support
growth
numer
virus
includ
respiratori
syncyti
viru
influenza
virus
parainfluenza
virus
enterovirus
adenovirus
cytomegaloviru
herp
simplex
viru
rhinoviru
mump
viru
measl
viru
human
coronaviru
human
metapneumoviru
inocul
cytopath
effect
examin
daili
two
week
furthermor
cpe
found
blind
passag
perform
anoth
two
week
system
rtpcr
also
perform
human
metapneumoviru
viru
isol
immunohistochemistrytissu
section
thick
deparaffin
treat
peroxidaseblock
reagent
dako
carpinteria
ca
minut
room
temperatur
incub
primari
antibodi
antibodi
optim
dilut
use
studi
follow
monoclon
antibodi
human
shinotest
antibodi
use
elisa
rage
chemicon
intern
inc
temecula
ca
thrombomodulin
dako
compani
ltd
glostrup
denmark
nichirei
co
tokyo
japan
antihuman
von
willebrand
factor
vwf
monoclon
antibodi
nichirei
tissu
incub
primari
antibodi
moist
chamber
overnight
react
polym
reagent
envison
kit
dako
carpinteria
ca
minut
room
temperatur
doubl
immunohistochem
stain
antigenantibodi
complex
visual
vector
red
vector
laboratori
burlingam
ca
mm
dab
describ
previous
morphometr
evaluationth
percentag
distribut
area
cell
immunoreact
thrombomodulin
among
immunoreact
estim
randomli
select
color
imag
magnif
case
use
digit
imag
analysi
system
lumina
vision
mitani
corpor
fukui
japan
statist
analysisfor
analysi
two
unpair
sampl
nonparametr
mannwhitney
u
test
use
signific
differ
defin
p
valu
repres
mean
sem
bronchoalveolar
lavag
fluid
balf
examin
studi
serial
sampl
two
four
time
acut
exacerb
ipf
patient
n
although
patient
treat
steroid
therapi
diagnosi
acut
exacerb
day
none
patient
mechan
ventil
treatment
measur
concentr
inflammatori
cytokin
consist
gcsf
gmcsf
find
two
seven
patient
illustr
figur
b
although
concentr
balf
low
earli
phase
acut
exacerb
well
continu
increas
even
steroid
therapi
pool
data
sampl
patient
concentr
balf
seven
patient
also
reveal
gradual
increas
acut
exacerb
figur
c
among
inflammatori
cytokin
examin
balf
sampl
increas
posit
correl
figur
attempt
viru
isol
balf
specimen
sampl
acut
exacerb
uncov
usual
pathogen
bacteria
virus
respiratori
syncyti
viru
influenza
virus
parainfluenza
virus
enterovirus
adenovirus
rhinoviru
cytomegaloviru
herp
simplex
viru
coronaviru
mump
viru
metapneumoviru
data
shown
immunohistochem
express
lung
tissu
patient
ipf
compar
two
patient
group
autopsi
lung
tissu
eight
patient
die
acut
exacerb
surgic
biopsi
lung
tissu
ten
patient
stabl
ipf
autopsi
lung
tissu
intens
cytoplasm
stain
observ
alveolar
macrophag
alveolar
epitheli
cell
without
nuclear
stain
figur
doubl
immunostain
marker
alveolar
capillari
endotheli
cell
clearli
reveal
distribut
cell
intens
express
near
capillari
augment
alveolar
septa
without
appar
fibrosi
figur
b
c
contrast
nuclear
stain
observ
surgic
lung
biopsi
patient
stabl
ipf
figur
averag
percentag
cell
immunoreact
mean
sem
autopsi
lung
tissu
ipf
patient
acut
exacerb
figur
surgic
biopsi
patient
stabl
ipf
cell
posit
without
signific
differ
compar
autopsi
p
howev
cell
immunoreact
case
surgic
biopsi
exhibit
nuclear
stain
figur
along
rare
cytoplasm
stain
significantli
differ
compar
percentag
nuclear
stain
autopsi
p
figur
distribut
cell
immunoreact
compar
rage
one
main
receptor
postmortem
lung
tissu
patient
ipf
acut
exacerb
cell
produc
coincid
cell
cytoplasm
express
figur
b
intens
express
rage
chiefli
observ
epitheli
cell
lesser
extent
capillari
endotheli
cell
figur
c
alveolar
capillari
immunoreact
express
figur
thrombomodulin
figur
b
reveal
consecut
section
typic
case
surgic
biopsi
immunoreact
thrombomodulin
almost
alway
sustain
alveolar
capillari
contrast
endotheli
express
thrombomodulin
appar
decreas
autopsi
lung
tissu
ipf
patient
acut
exacerb
figur
c
morphometr
analysi
use
digit
imag
analyz
system
clearli
reveal
decreas
immunoreact
thrombomodulin
compar
autopsi
lung
tissu
ipf
patient
die
acut
exacerb
n
comparison
control
n
even
biopsi
lung
tissu
stabl
ipf
patient
n
signific
differ
found
stabl
ipf
patient
normal
control
term
thrombomodulin
reactiv
figur
e
first
report
persist
elev
onset
acut
exacerb
lung
patient
ipf
mediat
produc
alveolar
macrophag
alveolar
type
ii
epitheli
cell
distribut
capillaryincreas
alveolar
lesion
capillari
endotheli
cell
exhibit
reduc
express
thrombomodulin
intrins
antagonist
gradual
increas
bronchoalveolar
lavag
fluid
onset
acut
exacerb
suggest
sever
plausibl
role
pathogenesi
acut
exacerb
ipf
one
role
late
mediat
acut
exacerb
concentr
low
initi
onset
acut
exacerb
although
virul
organ
virus
detect
bronchoalveolar
lavag
fluid
examin
studi
patient
flulik
symptom
day
onset
acut
exacerb
caus
triggerlik
effect
fulmin
inflamm
similar
acut
lung
injuri
gradual
increas
epitheli
line
fluid
lung
initi
onset
lung
injuri
also
report
experiment
clinic
acut
lung
injuri
although
releas
macrophag
respons
viral
infect
gradual
increas
observ
studi
consid
induc
passiv
releas
necrot
alveolar
type
ii
epitheli
cell
activ
secret
alveolar
macrophag
respons
oxid
stress
without
prove
molecular
mechan
increas
absenc
virul
viru
cytoplasm
stain
significantli
increas
cell
acut
exacerb
contrast
role
promot
sever
inflamm
report
promot
tissu
repair
regener
importantli
induc
migrat
stem
cell
toward
inflam
region
promot
repair
regener
exampl
smooth
muscl
cell
induc
prolifer
rapid
chang
cellular
architectur
result
cell
migrat
interestingli
mani
restor
effect
mediat
receptor
eg
rage
mediat
proinflammatori
properti
molecul
consid
recent
report
loss
rage
contribut
pulmonari
fibrosi
increas
alveolar
fluid
may
induc
fibrogenesi
receptor
tolllik
famili
receptor
tlr
gradual
increas
posit
correl
alveolar
fluid
acut
exacerb
may
also
contribut
fibroprolifer
thought
involv
regen
effect
cours
deni
point
plausibl
treatment
includ
steroid
therapi
patient
hospit
onset
acut
exacerb
might
affect
gradual
increas
addit
correl
concentr
andor
balf
diseas
sever
acut
exacerb
ipf
left
expect
observ
cell
cytoplasm
express
distribut
alveolar
capillari
augment
lesion
endotheli
cell
display
reduc
express
thrombomodulin
intrins
antagonist
acut
exacerb
report
previous
even
though
neutrophil
could
origin
acut
lung
injuri
addit
alveolar
epitheli
cell
alveolar
macrophag
concentr
besid
capillari
elev
capillari
augment
lesion
ipf
patient
suscept
acut
lung
injuri
capillari
reduc
abil
antagon
also
vegf
elev
augment
lesion
loosen
tight
junction
endotheli
cell
induc
leakag
decreas
express
thrombomodulin
anticoagul
well
may
readili
induc
coagul
capillari
augment
lesion
frequent
occur
case
acut
exacerb
ipf
patient
conclud
result
increas
lung
ipf
patient
acut
exacerb
alveolar
capillari
augment
lesion
decreas
express
thrombomodulin
intrins
inhibitor
may
exacerb
alveolar
damag
fibrogenesi
